ESMO 2019 Expert Video Report on Ovarian cancer

Reporting from ESMO 2019 Congress, Nicoletta Colombo comments the results from 3 positive studies with addition of the PARP inhibitors, olaparib, niraparib or veliparib in front-line management and maintenance therapy of women with advanced ovarian cancer. She believes that the results will change the current treatment algorithm and that in the future PARP inhibitors will be incorporated in first-line treatment of all patients with advanced ovarian cancer and not only in those with BRCA positive tumours.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings